Tarsus Pharmaceuticals Inc
TARS
Company Profile
Business description
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Contact
15440 Laguna Canyon Road
Suite 160
IrvineCA92618
USAT: +1 949 418-1801
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
323
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
stocks
Here’s 3 Top Rated ASX shares for 2026
As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 22.30 | 0.25% |
| CAC 40 | 8,218.50 | 15.42 | -0.19% |
| DAX 40 | 25,066.26 | 56.00 | -0.22% |
| Dow JONES (US) | 48,996.08 | 466.00 | -0.94% |
| FTSE 100 | 10,023.95 | 24.26 | -0.24% |
| HKSE | 26,149.31 | 309.64 | -1.17% |
| NASDAQ | 23,584.28 | 37.10 | 0.16% |
| Nikkei 225 | 51,117.26 | 844.72 | -1.63% |
| NZX 50 Index | 13,716.86 | 1.84 | 0.01% |
| S&P 500 | 6,920.93 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,720.80 | 18.20 | 0.21% |
| SSE Composite Index | 4,082.98 | 2.79 | -0.07% |